Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 5;16(1):133.
doi: 10.1186/s12955-018-0951-6.

Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review

Fatima Isa  1 , Grace M Turner  2 , Geetinder Kaur  2 , Derek Kyte  3 , Anita Slade  2   4 , Tanya Pankhurst  5 , Larissa Kerecuk  6 , Thomas Keeley  7 , James Ferguson  4   5 , Melanie Calvert  2   4
Affiliations

Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review

Fatima Isa et al. Health Qual Life Outcomes. .

Abstract

Background: Primary Sclerosing Cholangitis (PSC) is a rare chronic, cholestatic liver condition in which patients can experience a range of debilitating symptoms. Patient reported outcome measures (PROMs) could provide a valuable insight into the impact of PSC on patient quality of life and symptoms. A previous review has been conducted on the quality of life instruments used in liver transplant recipients. However, there has been no comprehensive review evaluating PROM use or measurement properties in PSC patients' to-date. The aim of the systematic review was to: (a) To identify and categorise which PROMs are currently being used in research involving the PSC population (b) To investigate the measurement properties of PROMs used in PSC.

Methods: A systematic review of Medline, EMBASE and CINAHL, from inception to February 2018, was undertaken. The methodological quality of included studies was assessed using the Consensus-based Standards for selection of health Measurement Instruments (COSMIN) checklist.

Results: Thirty-seven studies were identified, which included 36 different PROMs. Seven PROMs were generic, 10 disease-specific, 17 symptom-specific measures and 2 measures on dietary intake. The most common PROMs were the Short form-36 (SF-36) (n = 15) and Chronic liver disease questionnaire (CLDQ) (n = 6). Only three studies evaluated measurement properties, two studies evaluated the National Institute of Diabetes Digestive and Kidney Diseases Liver Transplant (NIDDK-QA) and one study evaluated the PSC PRO; however, according to the COSMIN guidelines, methodological quality was poor for the NIDDK-QA studies and fair for the PSC PRO study.

Conclusion: A wide variety of PROMs have been used to assess health-related quality of life and symptom burden in patients with PSC; however only two measures (NIDDK-QA and PSC PRO) have been formally validated in this population. The newly developed PSC PRO requires further validation in PSC patients with diverse demographics, comorbidities and at different stages of disease; however this is a promising new measure with which to assess the impact of PSC on patient quality of life and symptoms.

Keywords: Cholestasis; PROSPERO (Registration Number: CRD42016036544).; Patient reported outcome measures (PROMs); Primary sclerosing cholangitis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
PRISMA flowchart describing the identification, selection and inclusion of studies on PROM assessment in Primary sclerosing Cholangitis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114(1):53–64. doi: 10.1093/bmb/ldv019. - DOI - PubMed
    1. Primary Sclerosing Cholangitis [http://rarediseases.org/rare-diseases/primary-sclerosing-cholangitis/].
    1. Ponsioen C. Diagnosis, prognosis, and Management of Primary Sclerosing Cholangitis. Gastroenterol Hepatol. 2013;9(7):453–465. - PMC - PubMed
    1. Singh S, Talwalkar JA. Primary Sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol. 2013;11(8):898–907. doi: 10.1016/j.cgh.2013.02.016. - DOI - PMC - PubMed
    1. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD: Pathogenesis of primary Sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013, 145(3):10.1053/j.gastro.2013.1006.1052. - PMC - PubMed

Publication types

LinkOut - more resources